News | January 07, 2023
KIMS invests further in Sarvejana Healthcare
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Seeks partnership between government and private medical colleges for providing superior medical education
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Subscribe To Our Newsletter & Stay Updated
